Result card

  • ECO6: What are the uncertainties surrounding the costs and economic evaluation(s) of IGG and its comparator(s)?
Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment
E0010
English
Guidance Resources

What are the uncertainties surrounding the costs and economic evaluation(s) of IGG and its comparator(s)?

Authors: Anna-Theresa Renner, Neill Booth, Esther Kraft, Ingrid Rosian-Schikuta, Matthias Schwenkglenks

Internal reviewers: Pseudo297 Pseudo297

Given the lack of available data and lack of published evidence on the efficacy and/or the effectiveness of the intervention, the researchers (and internal reviewers) of this ‘Costs and economic evaluation’ domain agreed that it would not be prudent to undertake research into costs or undertake an economic evaluation.

Renner A et al. Result Card ECO6 In: Renner A et al. Costs and economic evaluation In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 7 February 2023]. Available from: http://corehta.info/ViewCover.aspx?id=267